Clinical Trial

Treatment as Prevention for Hepatitis C in Iceland

Study acronym: TraPHepC
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2020 (before its estimated December 2021 completion). Its status may not reflect the trial's current state.
Summary
The main aim of this study is to test in the Icelandic population the hypothesis that a nationwide treatment program which offers effective treatment to all known cases of Hepatitis C with the aim of halting HCV (Hepatitis C virus) transmission will lead to a reduction in incidence and disease burden associated with chronic HCV infection.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2016-01-05; most recent amendment 2020-09-24.
Status change: Not Yet Recruiting → Recruiting 2016-02-18
Trial Details
NCT Number NCT02647879
Lead Sponsor Landspitali University Hospital
Collaborators: National Center of Addiction Medicine (SAA)
Conditions Hepatitis C
Enrollment 1,000 participants
Start Date 2016-01
Primary Completion 2021-12 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2020-09-25